Today: 9 June 2026
Browse Category

LSE:GSK 11 December 2025 - 5 January 2026

London Stock Exchange Poised for Year-End Reopen as FTSE 100 Holds Near 9,871 and 2026 IPO Hopes Build

London Stock Exchange Poised for Year-End Reopen as FTSE 100 Holds Near 9,871 and 2026 IPO Hopes Build

The FTSE 100 closed at 9,870.68 in a muted, low-volume session ahead of the Christmas break, down about 0.2%. Despite the quiet finish, the index is up 20.7% for 2025, on track for a fifth consecutive yearly gain. U.S. markets ended Friday nearly flat, while gold and silver hit new records. London trading resumes Monday amid thin liquidity and strong commodity moves.
28 December 2025
···
London Stock Exchange Update: FTSE 100 Near Record Highs After a Strong 2025 — What to Watch When Trading Reopens

London Stock Exchange Update: FTSE 100 Near Record Highs After a Strong 2025 — What to Watch When Trading Reopens

The London Stock Exchange remains closed for the weekend and will reopen at 8:00 a.m. London time on Monday, December 29. The FTSE 100 ended the Christmas Eve half-day at 9,870.68, down 0.2%. The index is on track for a 20.7% annual gain, outperforming the S&P 500. The Bank of England cut its policy rate to 3.75% in December.
27 December 2025
···
GSK plc Stock (NYSE: GSK, LSE: GSK): Latest News, Forecasts, and Key Catalysts as of Dec. 26, 2025

GSK plc Stock (NYSE: GSK, LSE: GSK): Latest News, Forecasts, and Key Catalysts as of Dec. 26, 2025

GSK’s U.S. ADR closed at $48.96 after the FDA approved its twice-yearly asthma drug Exdensur, but withheld approval for a related use. The company also reached a U.S. drug-pricing deal affecting its respiratory products and reported progress on vaccine expansion in Europe. London trading paused for holidays. Shingrix faces new competition.
26 December 2025
···
UK Stock Market Today: FTSE 100 Pauses for Boxing Day as Investors Weigh Retail Signals, Precious-Metals Surge and 2026 Outlook (26 December 2025)

UK Stock Market Today: FTSE 100 Pauses for Boxing Day as Investors Weigh Retail Signals, Precious-Metals Surge and 2026 Outlook (26 December 2025)

The London Stock Exchange is closed Friday for Boxing Day, halting UK trading after a shortened Christmas Eve session where the FTSE 100 slipped 0.2%. Investors are watching global moves and a spike in precious metals, which could impact London-listed miners when trading resumes. BP agreed to sell a 65% stake in Castrol to Stonepeak for about $6 billion. The FTSE 100 is on track for a roughly 21% gain in 2025.
26 December 2025
·····
UK Stock Market Preview for 26 December 2025: Boxing Day Closure, FTSE 100 Drivers, Sterling Moves, Oil Pressure and the BoE Outlook

UK Stock Market Preview for 26 December 2025: Boxing Day Closure, FTSE 100 Drivers, Sterling Moves, Oil Pressure and the BoE Outlook

The London Stock Exchange will be closed on Friday, 26 December 2025, for Boxing Day. In the last session before the break, the FTSE 100 fell 0.2%. BP agreed to sell a 65% stake in Castrol to Stonepeak for about $6 billion, valuing Castrol at $10.1 billion. UK traders will return after the holiday to a market influenced by global moves and BP’s deal.
25 December 2025
····
United Kingdom Stock Market Today: FTSE 100 Holiday Pause, BP Castrol Deal and 2026 Outlook (25 Dec 2025)

United Kingdom Stock Market Today: FTSE 100 Holiday Pause, BP Castrol Deal and 2026 Outlook (25 Dec 2025)

The London Stock Exchange is closed for Christmas and Boxing Day, with trading set to resume after the long weekend. The FTSE 100 slipped 0.2% in a quiet half-day session on Christmas Eve. BP agreed to sell a 65% stake in Castrol to Stonepeak for about $6 billion, valuing Castrol at $10.1 billion. The Bank of England recently cut rates to 3.75%.
25 December 2025
····
GSK plc Stock News and Forecast (Dec. 20, 2025): TrumpRx Pricing Deal, Exdensur FDA Approval, Buybacks, and Analyst Targets

GSK plc Stock News and Forecast (Dec. 20, 2025): TrumpRx Pricing Deal, Exdensur FDA Approval, Buybacks, and Analyst Targets

GSK agreed to a U.S. drug-pricing deal covering its respiratory portfolio, securing a three-year exemption from tariffs and pledging lower Medicaid prices and direct-to-consumer discounts. The company also received fresh FDA approval for a severe asthma drug and expanded vaccine indications in Europe. GSK’s ADR closed Friday, Dec. 19, at $48.61.
20 December 2025
···
GSK Stock News Today (Dec. 18, 2025): Buyback Update, New FDA Approvals, and Analyst Forecasts for GSK plc

GSK Stock News Today (Dec. 18, 2025): Buyback Update, New FDA Approvals, and Analyst Forecasts for GSK plc

GSK said Thursday it bought 235,000 shares on Dec. 17 as part of its ongoing buyback, bringing total repurchases since Sept. 30 to over 14 million shares. GSK’s ADR traded at $48.71 in New York, down 0.13%. The company reported 239.6 million shares now held in treasury. Earlier this week, the FDA approved GSK’s Exdensur for severe asthma.
18 December 2025
··
GSK Stock News Today (Dec. 17, 2025): FDA Approves Twice‑Yearly Asthma Drug Exdensur as Analysts Reassess GSK plc’s 2026 Outlook

GSK Stock News Today (Dec. 17, 2025): FDA Approves Twice‑Yearly Asthma Drug Exdensur as Analysts Reassess GSK plc’s 2026 Outlook

The FDA approved GSK’s Exdensur (depemokimab-ulaa) on Dec. 17 as a twice-yearly add-on treatment for severe eosinophilic asthma in patients 12 and older. Phase III trials showed up to 58% fewer annual asthma exacerbations versus placebo. The FDA declined approval for a second indication, chronic rhinosinusitis with nasal polyps. GSK faces a leadership change Jan. 1, 2026.
17 December 2025
··
GSK plc Stock News Today (16.12.2025): Exdensur UK Approval Puts GSK Shares in Focus as FDA Decision Looms

GSK plc Stock News Today (16.12.2025): Exdensur UK Approval Puts GSK Shares in Focus as FDA Decision Looms

GSK shares closed at 1,833.50p in London on Dec. 15, up 0.49%, with the US ADR trading near $49.24. The UK approved Exdensur (depemokimab), the first twice-yearly asthma biologic, for asthma and chronic rhinosinusitis with nasal polyps. European and US regulators also advanced GSK’s respiratory and vaccine programs. GSK’s stock is up nearly 38% over the past year.
16 December 2025
··
GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead

GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead

GSK faces a key FDA decision on depemokimab for severe asthma and nasal polyps on Dec. 16, following recent EU regulatory backing for the drug and other respiratory products. GSK ADRs last traded at $48.81, while London shares opened at 1,816.50p. Analysts are watching for potential shifts in revenue forecasts and valuation as regulatory outcomes approach.
15 December 2025
··
GSK Stock News & Forecast (Week Ahead): CHMP Endorsements, FDA Label Expansion, Buyback Updates — Updated Dec. 14, 2025

GSK Stock News & Forecast (Week Ahead): CHMP Endorsements, FDA Label Expansion, Buyback Updates — Updated Dec. 14, 2025

GSK closed at 1,824.5p in London on Dec. 12, up about 1% for the week, despite a 2% drop on Dec. 9. The company secured three positive CHMP opinions in Europe, including for depemokimab in severe asthma and Arexvy’s expanded use in adults 18+. GSK’s U.S. ADR last traded at $48.81. EU decisions on these products are expected in early 2026.
14 December 2025
···
GSK Stock News Today (Dec. 12, 2025): Arexvy EU Expansion, Blujepa FDA Approval, Analyst Forecasts and What’s Next

GSK Stock News Today (Dec. 12, 2025): Arexvy EU Expansion, Blujepa FDA Approval, Analyst Forecasts and What’s Next

GSK shares traded near $48.88 Friday as the company reported key regulatory wins. The EMA’s CHMP backed expanding Arexvy’s RSV vaccine to all adults 18+ in Europe, with a final decision expected in February. The FDA also approved Blujepa (gepotidacin) for gonorrhea, marking the first new antibiotic class for the infection in decades. Analyst consensus sees Arexvy sales rising to £1.17 billion by 2031.
12 December 2025
··
GSK’s Emma Walmsley Hails US as ‘Best Place to Invest’ as UK Pharma Faces Tariffs, Rebate Cuts and a Fight for Jobs

GSK’s Emma Walmsley Hails US as ‘Best Place to Invest’ as UK Pharma Faces Tariffs, Rebate Cuts and a Fight for Jobs

GSK chief executive Emma Walmsley said the US is now the top destination for pharmaceutical investment, warning Britain risks falling further behind. Walmsley cited the US and China as key growth markets and confirmed GSK will invest $30 billion in the US by 2030. Her comments follow similar moves by AstraZeneca and recent UK government efforts to retain drug industry investment.
11 December 2025
··
1 2 3 4

Stock Market Today

  • Great Western Mining Issues TR-1 Major Shareholder Disclosure
    June 9, 2026, 10:36 AM EDT. Great Western Mining (GWMOF) announced a TR-1 notification of major holdings on June 9, 2026, via the Regulatory News Service (RNS) in Dublin. This disclosure highlights significant shareholdings in the company, providing investors with transparency on ownership stakes. The official document detailing the holdings is accessible via the London Stock Exchange website, ensuring market participants can review the full data. Such filings comply with regulatory requirements to keep the market informed of notable shareholder positions and maintain market integrity. The TR-1 form is a standard channel for reporting these substantial holdings in UK-listed companies.

Latest articles

Autozi Shares Jump 400%, Filing Flags Risks for AZI

Autozi Shares Jump 400%, Filing Flags Risks for AZI

9 June 2026
Autozi Internet Technology shares soared over 400% to $5.69 in early Nasdaq trading after a 10-for-1 share consolidation slashed its share count to about 4.49 million, but the surge contrasts with a 63.1% revenue drop, 82.5% plunge in gross profit, and widened net loss, with the company warning of “substantial doubt” about its ability to continue as a going concern.
Redwire Shares Slip After $500 Million Stock Offering Filed

Redwire Shares Slip After $500 Million Stock Offering Filed

9 June 2026
Redwire Corp shares plunged 6.5% to $17.37 after launching a $500 million at-the-market stock program, raising dilution risks for investors as the company seeks flexible funding despite recent record backlog and strong revenue growth; the drop contrasted with gains at other space stocks, highlighting investor concern over potential share issuance.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

9 June 2026
Nuvalent shares soared 38.9% to $122.93, just below GSK’s $124-a-share cash offer after the $10.6 billion buyout was announced, as investors bet on the deal closing with Nuvalent’s two lead lung-cancer drugs already under FDA review and a 40% premium to the last closing price driving the morning’s merger-arb trade.
Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
Go toTop